Jefferies Downgrades MEI Pharma (MEIP) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MEIP Hot Sheet
Price: $3.07 --0%
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Jefferies analyst Chris Howerton downgraded MEI Pharma (NASDAQ: MEIP) from Hold to Underperform with a price target of $0.10 (from $0.40).
For an analyst ratings summary and ratings history on MEI Pharma click here. For more ratings news on MEI Pharma click here.
Shares of MEI Pharma closed at $0.35 yesterday.
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- Third Coast Bancshares Inc (TCBX) PT Lowered to $54 at StoneX
- AppFolio (APPF) PT Raised to $250 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
